AstraZeneca PLC (BUE:AZN)
ARS 42025 -50 (-0.12%) Market Cap: 219.46 Tn Enterprise Value: 245.64 Tn PE Ratio: 33.69 PB Ratio: 5.51 GF Score: 64/100

AstraZeneca PLC at ASCO Virtual Scientific Program Transcript

Jun 01, 2020 / 03:00PM GMT
Release Date Price: ARS214.5
Craig Marks;David Fredrickson
AstraZeneca PLC - Senior Director of IR;AstraZeneca PLC - Executive

Hi, everyone. I'm Craig Marks from the IR team. Welcome. I'll be moderating the session today. I'd like to welcome you to virtual breakout 1 on Tagrisso and immuno-oncology. Today I'm joined by Dave Fredrickson, EVP for our Oncology business unit; and Cristian Massacesi, Senior Vice President, Late Development Oncology. We have until 5 past the hour, and we'll start with a short presentation with the majority of the time allocated for Q&A. The presentation materials are available on our website as well as recording of this session.

This event is strictly for invited sell-side analysts and institutional investors. Therefore, if you are a journalist, consultant, or employee of another pharmaceutical company, please disconnect now. (Operator Instructions)

Turning to the next slide, Slide 2. You can see our safe harbor statement and forward-looking statement disclaimer that we are using today. I'm now very happy to hand over to Dave to begin the session.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot